BridgeMD
Influence of Argipressin on blood loss during liver resection; a double-blinded, randomized, placebo-controlled trial (ARG-01)
EU CTIS ID: 2024-514332-25-00
What this study is testing
To determine if infusion of Argipressin during hepatic resection surgery reduces blood loss compared to placebo.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participant planned for hepatic resection (open or laparoscopic, regardless of indication for surgery).
- Age ≥18 years.
- American Society of Anaesthesiologists (ASA) class I-III.
- Signed informed consent form.
You likely can't join if
- Participant does not understand the given information, and/ or cannot give written informed consent.
- Patients with systemic inflammatory disease, inflammatory bowel disease or preoperative corticosteroid treatment will not be eligible for the subgroups where cytokines and interleukins are investigated.
- Simultaneous operation of tumor with other localization, or surgery for superficial single hepatic tumor less than 2 cm, expected to be of short duration and with minimal blood loss.
- Terminal kidney failure (estimated preoperative GFR< 15 ml/min).
- Pregnancy or lactation.
- Known allergy to Empressin®.
See the full eligibility criteria
- Participant planned for hepatic resection (open or laparoscopic, regardless of indication for surgery).
- Age ≥18 years.
- American Society of Anaesthesiologists (ASA) class I-III.
- Signed informed consent form.
- Participant does not understand the given information, and/ or cannot give written informed consent.
- Patients with systemic inflammatory disease, inflammatory bowel disease or preoperative corticosteroid treatment will not be eligible for the subgroups where cytokines and interleukins are investigated.
- Simultaneous operation of tumor with other localization, or surgery for superficial single hepatic tumor less than 2 cm, expected to be of short duration and with minimal blood loss.
- Terminal kidney failure (estimated preoperative GFR< 15 ml/min).
- Pregnancy or lactation.
- Known allergy to Empressin®.
- Patient included in other interventional study, interacting with the endpoints in the present study, or previous randomization in this study.
- Hyponatremia (S-Na < 130 mmol/L).
- Patient considered ineligible for other surgical or medical reason.
- Present infection.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.